ARTCLINE Completes Patient Recruitment for ReActIF-ICE Study on Septic Shock

Artcline GmbH has reached a significant milestone in its clinical study for septic shock treatment. The recruitment of 142 patients for the ReActIF-ICE study has concluded. This study focuses on ARTICE® therapy, which uses immune cells from healthy donors to aid patients' immune systems affected by septic shock. The 90-day follow-up phase is in progress, with data evaluation to follow.

The study, conducted at 20 intensive care centers, aims to introduce a new therapeutic option for septic shock. The ARTICE® therapy strives to reduce mortality rates associated with septic shock. Results will be shared at the DIVI Congress in December 2026.

Prof. Daniel A. Reuter, the study's principal investigator, highlighted the potential benefits of ARTICE® therapy. Despite advancements, sepsis remains a significant health challenge globally, with high mortality rates. ARTCLINE is committed to addressing this need through innovative therapies.